Switching protease inhibitors to rilpivirine in HIV‐positive individuals with complete viral suppression and without prior HIV drug resistance in a resource‐limited setting: a randomized controlled trial

INTRODUCTION: Prior to the availability of rilpivirine (RPV), patients who could not tolerate efavirenz and nevirapine (NVP) were treated with protease inhibitor (PI)‐based antiretroviral therapy (ART). Dyslipidaemia and other metabolic complications are commonly associated with PI use. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Palanuphap, Kulissara, Sungkanuparph, Somnuek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150595/
https://www.ncbi.nlm.nih.gov/pubmed/32277868
http://dx.doi.org/10.1002/jia2.25462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150595/
https://www.ncbi.nlm.nih.gov/pubmed/32277868
http://dx.doi.org/10.1002/jia2.25462

Ejemplares similares